D. Ferrigno

发表

Hepatic brucelloma.

L. Fenoglio, C. Bracco, R. Melchio, 2013, The Lancet. Infectious diseases.

Therapeutic options for regionally advanced non-small cell lung cancer.

D. Ferrigno, G. Buccheri, G. Buccheri, 1996, Lung cancer.

Prognostic ffactors iin llung c cancer: T Tables a and C Comments

D. Ferrigno, G. Buccheri, 1994 .

Prognostic value of the tissue polypeptide antigen in lung cancer.

D. Ferrigno, G. Buccheri, G. Buccheri, 1992, Chest.

Lung tumor markers of cytokeratin origin: an overview.

D. Ferrigno, G. Buccheri, 2001, Lung cancer.

Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?

D. Ferrigno, G. Buccheri, G. Buccheri, 2000, Lung cancer.

Primary hepatic carcinoid: a case report and literature review.

F. Pomero, L. Fenoglio, C. Bracco, 2009, World journal of gastroenterology.

Cytokeratin-derived markersof lung cancer

D. Ferrigno, G. Buccheri, 2001 .

Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squamous cell lung cancer.

D. Ferrigno, G. Buccheri, G. Buccheri, 1993, Lung cancer.

Imaging lung cancer by scintigraphy with indium 111‐labeled F(ab')2 fragments of the anticarcinoembryonic antigen monoclonal antibody F023C5

A. Biggi, D. Ferrigno, A. Comino, 1992, Cancer.

Serum tumour markers in lung cancer: history, biology and clinical applications.

A. Biggi, D. Ferrigno, G. Buccheri, 1994, The European respiratory journal.

Serum ttumour m markers iin llung ccancer: history, bbiology aand cclinical aapplications

A. Biggi, D. Ferrigno, G. Buccheri, 1994 .

Yield of Total Body GA-67 Scintigraphy in the Staging of Non-Small Cell Lung Cancer

Antonio Curcio, D. Ferrigno, G. Buccheri, 1989, Tumori.

Detection of suspected primary lung cancer by scintigraphy with indium-111-anti-carcinoembryonic antigen monoclonal antibodies (type F023C5)

A. Biggi, D. Ferrigno, A. Comino, 1991, Journal of Nuclear Medicine.

Lumbar muscle metastasis from lung cancer--report of a case.

D. Ferrigno, G. Buccheri, 1992, Acta oncologica.

Continuation of chemotherapy versus supportive care alone in patients with inoperable non‐small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study

A. Curcio, Antonio Curcio, D. Ferrigno, 1989, Cancer.

A comprehensive evaluation of serum ferritin levels in lung cancer patients

D. Ferrigno, G. Buccheri, 1992 .

Pasteurella multocida infection in a cirrhotic patient: case report, microbiological aspects and a review of literature.

F. Pomero, L. Fenoglio, D. Ferrigno, 2009, Advances in medical sciences.

Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma

A. Curcio, D. Ferrigno, A. Sartoris, 1986 .

Clinical applications of serum markers for lung cancer.

D. Ferrigno, D Ferrigno, G Buccheri, 1995, Respiratory medicine.

Prognostic factors in lung cancer: tables and comments.

D. Ferrigno, D Ferrigno, G Buccheri, 1994, The European respiratory journal.

The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer. Diagnostic yield and comparison with conventional staging methods.

D. Ferrigno, G. Buccheri, 1995, Chest.

Monitoring lung cancer with tissue polypeptide antigen: an ancillary, profitable serum test to evaluate treatment response and posttreatment disease status.

D. Ferrigno, G. Buccheri, G. Buccheri, 1995, Lung cancer.

Usefulness of tissue polypeptide antigen in staging, monitoring, and prognosis of lung cancer.

D. Ferrigno, G. Buccheri, G. Buccheri, 1988, Chest.

Tissue polypeptide specific antigen (TPS) and objective response to treatment in solid tumors

G. Pravettoni, D. Ferrigno, G. Buccheri, 1992, The International journal of biological markers.

The difficult choice of chemotherapy in patients with unresectable non-small-cell lung cancer

C. Brunelli, M. Tamburini, D. Ferrigno, 2000, Supportive Care in Cancer.

Serum ferritin levels in lung cancer patients.

D. Ferrigno, G. Buccheri, 1992, European journal of cancer.

Prognostic significance of blood coagulation tests in lung cancer.

D. Ferrigno, G. Buccheri, I. Ricca, 2001, The European respiratory journal.

Vinorelbine in elderly patients with inoperable non-small cell lung cancer: A phase II study

D. Ferrigno, G. Buccheri, 2000 .

Vinorelbine in elderly patients with inoperable nonsmall cell lung carcinoma

D. Ferrigno, G. Buccheri, 2000, Cancer.

Is the MVP regimen less active than previously described? Results of a phase II study in advanced non-small cell lung cancer.

D. Ferrigno, G. Buccheri, 1996, Acta oncologica.

A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non‐small cell lung cancer

D. Ferrigno, G. Buccheri, A. Rosso, 1993, Cancer.

Further evidence in favour of chemotherapy for inoperable non-small cell lung cancer☆

D. Ferrigno, G. Buccheri, F. Vola, 1990 .

Efficacy of platinum-based regimens in non-small cell lung cancer. A negative report from the Cuneo Lung Cancer Study Group.

D. Ferrigno, G. Buccheri, G. Buccheri, 1997, Lung cancer.

Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution.

M. Tamburini, D. Ferrigno, D Ferrigno, 1996, European journal of cancer.

Cranial computed tomography as a part of the initial staging procedures for patients with non-small-cell lung cancer.

D. Ferrigno, G. Buccheri, G. Buccheri, 1994, Chest.

Vertebroplasty in the treatment of osteoporosis vertebral fractures: Report on 52 cases

F. Pomero, L. Fenoglio, G. Lingua, 2008, Journal of endocrinological investigation.

Prognostic factors of small cell lung cancer.

D. Ferrigno, G. Buccheri, 2004, Hematology/oncology clinics of North America.

An Indirect Marker of Tumor Activity

D. Ferrigno, P. Marino, A. Preatoni, 2017 .

Soluble interleukin 2 receptor in lung cancer. An indirect marker of tumor activity?

D. Ferrigno, G. Buccheri, P. Marino, 1991, Chest.

Importance of weight loss definition in the prognostic evaluation of non-small-cell lung cancer.

D. Ferrigno, G. Buccheri, 2001, Lung cancer.

A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer. Cuneo Lung Cancer Study Group (CuLCaSG)

D. Ferrigno, G. Buccheri, 1994, European journal of cancer.

Plasma levels of D‐dimer in lung carcinoma

D. Ferrigno, P. Torchio, G. Buccheri, 2003, Cancer.

A shift from distal to proximal neoplasia in the colon: a decade of polyps and CRC in Italy

L. Fenoglio, C. Senore, D. Ferrigno, 2010, BMC gastroenterology.

Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC).

D. Ferrigno, G. Buccheri, C. Giordano, 2003, Lung cancer.

Hematologic counts and clinical correlates in 1201 newly diagnosed lung cancer patients.

D. Ferrigno, G. Buccheri, 2003, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

Prognostic value of stage grouping and TNM descriptors in lung cancer.

D. Ferrigno, G. Buccheri, 2000, Chest.

Haemostatic abnormalities in lung cancer: prognostic implications.

D. Ferrigno, C. Ginardi, G. Buccheri, 1997, European journal of cancer.

The patient's perception of his own quality of life might have an adjunctive prognostic significance in lung cancer.

C. Brunelli, M. Tamburini, D. Ferrigno, 1995, Lung cancer.

Serum biomarkers of non-neuron-endocrine origin in small-cell lung cancer: a 16-year study on carcinoembryonic antigen, tissue polypeptide antigen and lactate dehydrogenase.

D. Ferrigno, G. Buccheri, 2000, Lung cancer.

Cisplatin and vinorelbine remains a valid option for the front-line chemotherapy treatment of NSCLC.

D. Ferrigno, G. Buccheri, C. Giordano, 2004, Anticancer research.

99mTC‐tetrofosmin scintigraphy in lung carcinoma staging and follow‐up evaluations

A. Biggi, D. Ferrigno, A. Francini, 2002, Cancer.

Lung cancer: clinical presentation and specialist referral time

D. Ferrigno, G. Buccheri, 2004, European Respiratory Journal.

Anthropometric measurements in non-small-cell lung cancer

D. Ferrigno, G. Buccheri, 2001, Supportive Care in Cancer.

Anti-CEA immunoscintigraphy might be more useful than computed tomography in the preoperative thoracic evaluation of lung cancer. A comparison between planar immunoscintigraphy, single photon emission computed tomography (SPECT), and computed tomography.

A. Biggi, G Buccheri, D. Ferrigno, 1993, Chest.

Lung tumour markers in oncology practice: a study of TPA and CA125

D. Ferrigno, G. Buccheri, 2002, British Journal of Cancer.

Anti-CEA immunoscintigraphy and computed tomographic scanning in the preoperative evaluation of mediastinal lymph nodes in lung cancer.

A. Biggi, D. Ferrigno, G. Buccheri, 1996, Thorax.

Clinical equivalence of two cytokeratin markers in mon-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments.

D. Ferrigno, P. Torchio, G. Buccheri, 2003, Chest.

Weekly chemotherapy with cisplatin and paclitaxel in advanced NSClC: a phase II study.

D. Ferrigno, M. Giordano, G. Buccheri, 2016, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

Nuclear medicine imaging in lung cancer.

A. Biggi, D. Ferrigno, G. Buccheri, 1997, International journal of oncology.

Aspects of quality-of-life in patients with lung-cancer - a 3 observer evaluation study.

D. Ferrigno, G. Buccheri, F. Vola, 1993, International journal of oncology.

Identifying patients at risk of early postoperative recurrence of lung cancer: a new use of the old CEA test.

D. Ferrigno, G. Buccheri, 2003, The Annals of thoracic surgery.

Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC).

D. Ferrigno, G. Buccheri, 2004, Lung cancer.

Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19‐9

Antonio Curcio, D. Ferrigno, G. Buccheri, 1987, Cancer.

Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer.

D. Ferrigno, G. Buccheri, 2001, The Journal of thoracic and cardiovascular surgery.

Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma

Antonio Curcio, D. Ferrigno, G. Buccheri, 1986, Cancer.

Tissue Polipetide Antigen (TPA) has a great prognostic capability in Lung Cancer (LC)

D. Ferrigno, G. Buccheri, 1991 .

Prognostic factors.

D. Ferrigno, G. Buccheri, 2004, Hematology/Oncology Clinics of North America.

A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non‐small cell lung cancer

D. Ferrigno, G. Buccheri, A. Rosso, 1993, Cancer.

Combination chemotherapy with methotrexate, adriamycin, cyclophosphamide and CCNU (MACC) for nonsmall cell lung cancer. 4-year experience with 92 patients.

A. Curcio, D. Ferrigno, G. Buccheri, 1989, Oncology.

Second-line weekly paclitaxel in patients with inoperable non-small cell lung cancer who fail combination chemotherapy with cisplatin.

D. Ferrigno, G. Buccheri, 2004, Lung cancer.

Chemotherapy with Cisplatin and Paclitaxel in Inoperable Non-small Cell Lung Cancer : An Extended Phase II Study *

D. Ferrigno, 2009 .

Prognostic significance of the serum protein content in lung cancer (LC)

D. Ferrigno, G. Buccheri, 1994 .